1887

oa South African Medical Journal - Suggested method of rendering butazolidin less harmful

 

Abstract

The theories applying to the use of a catalyst ferrous iron, in activating the redux potential of vitamin C have been discussed. Implementation of the redux potential is claimed to neutralize the progress of agranulocytosis and allied blood disorders such as thrombocytopoenia, capillary fragility, etc. Two cases being treated for rheumatoid arthritis with butazolidin and vitamin C developed evidence of agranulocytosis. This complication of the arthritic therapy was overcome by the addition of a catalyst ferrous iron to the vitamin and butazolidin. No relapse has occurred during treatment persevered with for some weeks. Further research and trial of the method is advocated.

Loading

Article metrics loading...

/content/m_samj/27/45/AJA20785135_29101
1953-11-01
2016-12-07
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error